Rational engineering of semiconductor QDs enabling remarkable 1 O 2 production for tumor-targeted photodynamic therapy

Shen, Yizhong; Sun, Yidan; Yan, Runqi; Chen, Erquan; Wang, Huan; Ye, Deju; Xu, Jing‐Juan; Chen, Hong‐Yuan

doi:10.1016/j.biomaterials.2017.09.026

Cited by 61 publications

(78 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…2C, almost no green uorescence appeared in the three control groups, indicating there was no adequate ROS generation in cells to oxidize no-uorescent DCFH-DA to uorescent dichlorouorescein (DCF). [31][32][33][34][35][36][37][38] In contrast, bright green uorescence emerged in Co-NRs group with light irradiation, suggesting the generation of ROS.…”

Section: Resultsmentioning

confidence: 93%

Self-assembled organic nanorods for dual chemo-photodynamic therapies

Zheng

et al. 2018

RSC Adv.

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 93%

Self-assembled organic nanorods for dual chemo-photodynamic therapies

Zheng

et al. 2018

RSC Adv.

View full text Add to dashboard Cite

show abstract

“…In another investigation, Shen et al developed a hybrid nanocomposite for tumor targeting, which consists of quantum dots-Zn-porphyrin nanocomplex. A fluorescent photosensitizer rhodamine 6G and near-infrared fluorophore (NIR775) were enclosed in folic-acid-decorated phospholipid polymers [28]. The developed system has a high payload of porphyrin, consequently resulting in exceptionally high 1 O 2 quantum yields.…”

Section: Targeted Cancer Chemotherapymentioning

confidence: 99%

Progress of Cancer Nanotechnology as Diagnostics, Therapeutics, and Theranostics Nanomedicine: Preclinical Promise and Translational Challenges

et al. 2020

View full text Add to dashboard Cite

Early detection, right therapeutic intervention, and simultaneous effectiveness mapping are considered the critical factors in successful cancer therapy. Nevertheless, these factors experience the limitations of conventional cancer diagnostics and therapeutics delivery approaches. Along with providing the targeted therapeutics delivery, advances in nanomedicines have allowed the combination of therapy and diagnostics in a single system (called cancer theranostics). This paper discusses the progress in the pre-clinical and clinical development of therapeutics, diagnostics, and theranostics cancer nanomedicines. It has been well evident that compared to the overabundance of works that claimed success in pre-clinical studies, merely 15 and around 75 cancer nanomedicines are approved, and currently under clinical trials, respectively. Thus, we also brief the critical bottlenecks in the successful clinical translation of cancer nanomedicines.

show abstract

“…The acidic environment (pH~5) of lysosomes makes it suitable for target therapies that control the release of drugs at acidic pH. Ligand conjugated nanoformulations majorly target the lysosomes via receptor mediated endocytosis (Shen et al, 2017). Mitochondria are known as the power house of cells, and researchers have therefore tried to enhance the ROS (reactive oxygen species) level, to induce mitochondrial damage, and blockage of the respiration in mitochondria, for the treatment of cancerous cells.…”

Section: Active Targetingmentioning

confidence: 99%

Membrane Trafficking and Subcellular Drug Targeting Pathways

Kumar¹,

Ahmad²,

Vyawahare³

et al. 2020

Front. Pharmacol.

View full text Add to dashboard Cite

The movement of micro and macro molecules into and within a cell significantly governs several of their pharmacokinetic and pharmacodynamic parameters, thus regulating the cellular response to exogenous and endogenous stimuli. Trafficking of various pharmacological agents and other bioactive molecules throughout and within the cell is necessary for the fidelity of the cells but has been poorly investigated. Novel strategies against cancer and microbial infections need a deeper understanding of membrane as well as subcellular trafficking pathways and essentially regulate several aspects of the initiation and spread of anti-microbial and anti-cancer drug resistance. Furthermore, in order to avail the maximum possible bioavailability and therapeutic efficacy and to restrict the unwanted toxicity of pharmacological bioactives, these sometimes need to be functionalized with targeting ligands to regulate the subcellular trafficking and to enhance the localization. In the recent past the scenario drug targeting has primarily focused on targeting tissue components and cell vicinities, however, it is the membranous and subcellular trafficking system that directs the molecules to plausible locations. The effectiveness of the delivery platforms largely depends on their physicochemical nature, intracellular barriers, and biodistribution of the drugs, pharmacokinetics and pharmacodynamic paradigms. Most subcellular organelles possess some peculiar characteristics by which membranous and subcellular targeting can be manipulated, such as negative transmembrane potential in mitochondria, intraluminal delta pH in a lysosome, and many others. Many specialized methods, which positively promote the subcellular targeting and restrict the off-targeting of the bioactive molecules, exist. Recent advancements in designing the carrier molecules enable the handling of membrane trafficking to facilitate the delivery of active compounds to subcellular localizations. This review aims to cover membrane trafficking pathways which promote the delivery of the active molecule in to the subcellular locations, the associated pathways of the subcellular drug delivery system, and the role of the carrier system in drug delivery techniques.

show abstract

Rational engineering of semiconductor QDs enabling remarkable 1 O 2 production for tumor-targeted photodynamic therapy

Cited by 61 publications

References 60 publications

Self-assembled organic nanorods for dual chemo-photodynamic therapies

Self-assembled organic nanorods for dual chemo-photodynamic therapies

Progress of Cancer Nanotechnology as Diagnostics, Therapeutics, and Theranostics Nanomedicine: Preclinical Promise and Translational Challenges

Membrane Trafficking and Subcellular Drug Targeting Pathways

Contact Info

Product

Resources

About